Abbott Laboratories (ABT) Set to Announce Earnings on Wednesday
Abbott Laboratories (NYSE:ABT) will release its Q316 earnings data on Wednesday, October 19th. Abbott Laboratories has set its FY16 guidance at $2.14-2.24 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.02. The business had revenue of $5.30 billion for the quarter, compared to the consensus estimate of $5.24 billion. Abbott Laboratories had a net margin of 11.08% and a return on equity of 15.11%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the firm posted $0.52 earnings per share. On average, analysts expect Abbott Laboratories to post $2.20 EPS for the current fiscal year and $0.09 EPS for the next fiscal year.
Abbott Laboratories (NYSE:ABT) opened at 40.59 on Tuesday. The stock has a 50 day moving average of $41.89 and a 200 day moving average of $41.37. Abbott Laboratories has a 52-week low of $36.00 and a 52-week high of $46.38. The stock has a market capitalization of $59.67 billion, a P/E ratio of 26.79 and a beta of 0.87.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/abbott-laboratories-abt-set-to-announce-earnings-on-wednesday.html
The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 15th. Stockholders of record on Friday, October 14th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 2.56%. The ex-dividend date is Wednesday, October 12th. Abbott Laboratories’s payout ratio is 68.87%.
Several equities research analysts have recently weighed in on ABT shares. Edward Jones raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, June 21st. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a report on Tuesday, July 5th. Barclays PLC reissued an “overweight” rating and set a $48.00 price objective on shares of Abbott Laboratories in a report on Tuesday, July 12th. Jefferies Group increased their price objective on shares of Abbott Laboratories from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, July 14th. Finally, Argus reissued a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Thursday, July 28th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Abbott Laboratories presently has an average rating of “Buy” and an average target price of $47.02.
In other Abbott Laboratories news, Chairman Miles D. White purchased 242,547 shares of the firm’s stock in a transaction dated Monday, July 25th. The stock was bought at an average cost of $43.18 per share, with a total value of $10,473,179.46. Following the purchase, the chairman now directly owns 2,010,517 shares of the company’s stock, valued at $86,814,124.06. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Daniel Gesua Sive Salvadori sold 815 shares of the firm’s stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $41.71, for a total transaction of $33,993.65. Following the transaction, the senior vice president now directly owns 59,791 shares of the company’s stock, valued at $2,493,882.61. The disclosure for this sale can be found here. Company insiders own 0.26% of the company’s stock.
Several institutional investors have recently modified their holdings of ABT. Jarislowsky Fraser Ltd boosted its position in shares of Abbott Laboratories by 780.3% in the second quarter. Jarislowsky Fraser Ltd now owns 18,800,322 shares of the healthcare product maker’s stock valued at $1,060,533,000 after buying an additional 16,664,605 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Abbott Laboratories by 16.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 36,209,595 shares of the healthcare product maker’s stock valued at $1,423,400,000 after buying an additional 5,115,232 shares in the last quarter. Westwood Holdings Group Inc. acquired a new position in shares of Abbott Laboratories during the second quarter valued at $162,264,000. TIAA CREF Investment Management LLC boosted its position in shares of Abbott Laboratories by 23.1% in the second quarter. TIAA CREF Investment Management LLC now owns 10,171,634 shares of the healthcare product maker’s stock valued at $399,847,000 after buying an additional 1,906,748 shares in the last quarter. Finally, AXA boosted its position in shares of Abbott Laboratories by 518.1% in the second quarter. AXA now owns 1,678,100 shares of the healthcare product maker’s stock valued at $65,966,000 after buying an additional 1,406,600 shares in the last quarter. 73.00% of the stock is owned by institutional investors.
About Abbott Laboratories
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.